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Binding of the molecular chaperone alphaB-crystallin to Abeta amyloid fibrils
inhibits fibril elongation
Abstract
The molecular chaperone αB-crystallin is a small heat-shock protein that is upregulated in response to a
multitude of stress stimuli, and is found colocalized with Aβ amyloid fibrils in the extracellular plaques
that are characteristic of Alzheimer's disease. We investigated whether this archetypical small heat-shock
protein has the ability to interact with Aβ fibrils in vitro. We find that αB-crystallin binds to wild-type Aβ42
fibrils with micromolar affinity, and also binds to fibrils formed from the E22G Arctic mutation of Aβ42.
Immunoelectron microscopy confirms that binding occurs along the entire length and ends of the fibrils.
Investigations into the effect of αB-crystallin on the seeded growth of Aβ fibrils, both in solution and on
the surface of a quartz crystal microbalance biosensor, reveal that the binding of αB-crystallin to seed
fibrils strongly inhibits their elongation. Because the lag phase in sigmoidal fibril assembly kinetics is
dominated by elongation and fragmentation rates, the chaperone mechanism identified here represents a
highly effective means to inhibit fibril proliferation. Together with previous observations of αB-crystallin
interaction with α-synuclein and insulin fibrils, the results suggest that this mechanism is a generic
means of providing molecular chaperone protection against amyloid fibril formation.
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Binding of the Molecular Chaperone aB-Crystallin to Ab Amyloid Fibrils
Inhibits Fibril Elongation
Sarah L. Shammas,†* Christopher A. Waudby,§ Shuyu Wang,† Alexander K. Buell,† Tuomas P. J. Knowles,†
Heath Ecroyd,{ Mark E. Welland,‡ John A. Carver,k Christopher M. Dobson,† and Sarah Meehan†
†
Department of Chemistry and ‡Nanoscience Centre, University of Cambridge, Cambridge, United Kingdom; §Department of Structural
Molecular Biology, University College London, London, United Kingdom; {School of Biological Sciences, University of Wollongong,
Wollongong, Australia; and kSchool of Chemistry and Physics, University of Adelaide, Adelaide, Australia

ABSTRACT The molecular chaperone aB-crystallin is a small heat-shock protein that is upregulated in response to a multitude
of stress stimuli, and is found colocalized with Ab amyloid fibrils in the extracellular plaques that are characteristic of Alzheimer’s
disease. We investigated whether this archetypical small heat-shock protein has the ability to interact with Ab fibrils in vitro. We
find that aB-crystallin binds to wild-type Ab42 fibrils with micromolar affinity, and also binds to fibrils formed from the E22G Arctic
mutation of Ab42. Immunoelectron microscopy confirms that binding occurs along the entire length and ends of the fibrils. Investigations into the effect of aB-crystallin on the seeded growth of Ab fibrils, both in solution and on the surface of a quartz crystal
microbalance biosensor, reveal that the binding of aB-crystallin to seed fibrils strongly inhibits their elongation. Because the lag
phase in sigmoidal fibril assembly kinetics is dominated by elongation and fragmentation rates, the chaperone mechanism identified here represents a highly effective means to inhibit fibril proliferation. Together with previous observations of aB-crystallin
interaction with a-synuclein and insulin fibrils, the results suggest that this mechanism is a generic means of providing molecular
chaperone protection against amyloid fibril formation.

INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of
senile dementia, affecting >26 million people worldwide
(1). This neurodegenerative condition is characterized by
fibrillar protein deposition in both extracellular plaques and
intracellular neurofibrillary tangles within the brain. The
major constituents of the extracellular plaques are amyloid-b
(Ab) peptides, which are 39–43 amino acid residue cleavage
products of the amyloid precursor protein (APP), an integral
membrane protein. The aggregation of these peptides is
thought to be critical to the pathogenesis of the disease (2).
However, other proteins, including small heat-shock proteins
(sHsps), a ubiquitous class of molecular chaperones, are also
found colocalized with Ab peptides in extracellular plaques
(3–7). For example, the most extensively studied sHsp,
aB-crystallin, (referred to as HSPB5 in the recently revised
systematic nomenclature of the sHsps) is present at increased
levels in the temporal and frontal lobes of postmortem AD
brains (3,4), with the majority being localized within astrocytes and oligodendrocytes (4,8), and in the neurons
surrounding senile plaques (8,9).
aB-Crystallin is found not only in the brain (10) but also in
many other regions of the human body, including the retina,
heart, skeletal muscle, skin, spinal cord, kidneys, lungs
(10–12), cochleae of the mammalian ear (13), and the lacrimal gland duct and tears (14). It is also a crucial component
of the eye lens, where it is found in particularly high concentrations (up to ~200 mg/ml) together with its fellow sHsp

Submitted December 30, 2010, and accepted for publication July 25, 2011.
*Correspondence: sls42@cam.ac.uk

aA-crystallin (15), with which it shares 57% sequence similarity (16). Of interest, aB-crystallin is associated with Ab
deposition in supranuclear cataracts in lenses from patients
with AD (17).
In its native state, aB-crystallin assembles to form a
heterogeneous mixture of oligomers ranging in size from
10 to 40 subunits, with the dominant populations containing
24–33 subunits (18). Each monomeric subunit is a 175
amino acid protein of ~20 kDa in mass and is composed
of an ~90-residue central b-sandwich domain (19), which
is termed the a-crystallin domain and is conserved between
all sHsps (16). The a-crystallin domain is flanked by variable N-terminal and C-terminal regions, with the latter containing an unstructured and highly flexible 12 amino acid
hydrophilic C-terminal extension at its extremity (20,21).
The C-terminal region is important for maintaining the solubility of the protein (21,22) and regulating intersubunit
interactions via the palindromic sequence centered about
the conserved I-X-I motif within the native oligomer (23).
As a result of the latter role, the C-terminal region may
have an important function in chaperone action as regulated
by subunit exchange (24,25). Transmission electron microscopy (TEM) shows native aB-crystallin oligomers to be
roughly spherical (26), and cryo-EM reconstructions reveal
a spherical protein shell averaging 13.5 nm in diameter with
an 8.5 nm hollow interior (27,28).
aB-Crystallin is upregulated in response to a multitude of
stress stimuli in vivo and has impressive chaperone abilities
in vitro (21). Interactions of aB-crystallin with many amorphously aggregating proteins in vitro have been extensively
documented (29). As an sHsp, it binds to partially folded
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proteins in an ATP-independent manner, sequestering them
from aggregation until ATP-dependent chaperones, such as
Hsp-70 and Hsp-90, have an opportunity to restore their
native state (21). aB-Crystallin may also be involved in targeting substrates for degradation, as has been reported for
other members of the sHsp chaperone family (30). Furthermore, aB-crystallin inhibits the growth of amyloid fibrils of
the type found in disease-associated plaques, such as in AD
(reviewed by Ecroyd and Carver (31)).
Amyloid fibrils are highly ordered linear protein aggregates with a cross-b core, typically having widths and
lengths of a few nanometers and micrometers, respectively
(32). Their assembly (from monomer) is a complex process,
and a variety of different species of varying toxicity have
been identified that may be intermediates in the pathway
(33), particularly during the earlier stages of aggregation,
including dimers and small oligomers (34–37), amyloidb-derived diffusible ligands (soluble nonfibrillar oligomers)
(38–40), and protofibrils (41,42) (soluble fibril-like oligomers). However, a highly effective model of fibril assembly
can be described by just three kinetic processes: 1), nucleation of fibril seeds from monomeric protein (by unspecified
pathways potentially involving oligomers); 2), elongation of
these structures by incorporation of additional monomers;
and 3), fragmentation of fibrils, which increases the number
of growth sites at the fibril ends and results in exponential
growth kinetics (43,44). Analysis of aggregation kinetics
in terms of these fundamental microscopic processes is
becoming increasingly important for elucidating the molecular basis of aggregate formation and the factors that can
influence its rate, and a variety of methodologies have
been developed to measure the individual processes in isolation (45,46). The lag phase in the growth kinetics can be bypassed if sufficient concentrations of preformed fibrils (or
seeds) are provided as templates for elongation and subsequent fragmentation, resulting in immediate fibril growth
(43). Amyloid fibrils are associated with many degenerative
diseases; however, such fibrils can also be formed from
nondisease-related proteins. The ability to form fibrils is
believed to be a generic property of the polypeptide backbone, although the propensity for such formation varies
significantly depending on factors such as the amino acid
sequence and solution conditions (47).
The Ab peptides have a favorable propensity for forming
amyloid fibrils (48). The sequential cleavage of APP by
b- and g-secretases often yields Ab peptides that are 40 or
42 residues long, with the latter isoform having greater
aggregation potential (2). Genetic mutations in the APPprocessing machinery, which increases the level of Ab42
or the ratio of Ab42/Ab40, result in a dramatically earlier
onset of AD (49,50), suggesting an important role for Ab
assembly in the pathogenic cascade. Genetic mutations
within the Ab sequence itself can also reduce the age of
disease onset by increasing the aggregation propensity of
the peptide. One such particularly aggregation-prone Ab
Biophysical Journal 101(7) 1681–1689
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peptide is Ab42 with the so-called Arctic mutation
(E22G). This mutation, which was found in a single family
in northern Sweden, gives rise to clinical features of earlyonset AD, reportedly because of a propensity to form protofibrillar species over fibrillar ones (42).
The observation that Ab and aB-crystallin are colocalized
in vivo (3,4) has led to concerted investigations into the effect
of aB-crystallin on Ab aggregation in vitro. A number of
apparently conflicting results have been reported (31), potentially because of differences in the experimental methods
used, including the method of purification and handling of
the Ab peptide, and the incubation conditions. Most studies
indicated that aB-crystallin is capable of inhibiting Ab fibril
formation (51–55), and recent work also showed a protective
effect on Ab-induced cytotoxicity (56). It is important to
consider the mechanism by which aB-crystallin exerts this
protective effect. As previously mentioned, several species
of Ab are present during the aggregation process. Differences in structure between the various Ab species are likely
to lead to different biophysical properties, such as exposed
hydrophobicity, and as such the interaction between aBcrystallin and Ab peptides is best examined for each Ab
species in isolation if possible. Investigators have examined
interactions between aB-crystallin and the Ab monomer
using analytical ultracentrifugation, which did not reveal
any complex formation (53). However, NMR studies identified a weak and transient interaction involving the hydrophobic core residues (17–21) of the Ab40 peptide (57).
We recently demonstrated that aB-crystallin binds to
amyloid fibrils formed by a-synuclein, the protein whose
aggregation is linked to Parkinson’s disease, and inhibits
their elongation (58). Given that an interaction between
aB-crystallin and Ab40 fibrils was previously identified
(53), with aB-crystallin preventing the seeded growth of
Ab40 and the nonseeded growth of the Ab42 variant (53),
we decided to study the interaction of these species to investigate whether fibril binding serves as a generic chaperone
mechanism. We identified the existence of a similar chaperone mechanism for preventing aggregation of Ab42 and
its early-onset disease-associated Arctic variant, Ab42arc.
Through the use of fluorescence assays and immunoelectron
microscopy, we found that aB-crystallin binds strongly to
fibrils composed of both Ab42 and Ab42arc peptides. Furthermore, we investigated the mechanistic implications of
this binding interaction directly by studying the effect of
aB-crystallin on the Ab42 amyloid fibril elongation phase
examined in isolation, both in solution using thioflavin T
(ThT) fluorescence, and on a surface using a quartz crystal
microbalance (QCM). We found that aB-crystallin binding
to Ab fibrils strongly inhibits their elongation. Because
the most effective means of extending the lag phase for
amyloid fibril growth is to reduce the elongation (or fragmentation) rate (43), this is likely to represent a highly successful (and generic) chaperone mechanism for suppressing
fibril proliferation.
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MATERIALS AND METHODS
The materials and methods used in this work are described in the Supporting Material.

A

RESULTS
Quantification of aB-crystallin binding
to Ab amyloid fibrils

B
[αB-Crystallin bound] (μM)

Initially, we investigated whether aB-crystallin was capable
of binding to Ab42 fibrils using a sedimentation assay. aBCrystallin was incubated in the presence of Ab42 fibrils
for 1 h at room temperature, and then the mixture was centrifuged under conditions that cause sedimentation of Ab
fibrils but not free aB-crystallin oligomers (Fig. S1).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) analysis (see Fig. 1 A) showed that there was
significantly less aB-crystallin in the supernatant in the
presence of Ab42 fibrils than in its absence, indicating that
aB-crystallin copellets with Ab42 fibrils. That this effect is
not simply nonspecific protein binding was indicated by
the fact that two control proteins of similar mass, i.e., green
fluorescent protein (GFP) and ubiquitin carboxyl-terminal
hydrolase isozyme L3 (UCH-L3), did not copellet under
these conditions (Fig. 1 A). A purely electrostatic effect
was also ruled out, because only a small change in sedimentation behavior was observed when the ionic strength of the
solution was increased (Fig. S2).
To quantify the stoichiometry and affinity of aB-crystallin
binding to Ab fibrils, we performed further sedimentation
experiments over a range of different aB-crystallin concentrations (with Ab fibril concentration held constant), and
determined the concentration of aB-crystallin remaining in
the supernatant by measuring its intrinsic tryptophan fluorescence (Ab has no tryptophan residues). Consistent with the
SDS-PAGE analysis (Fig. 1 A), a highly reproducible reduction in supernatant fluorescence was observed for aB-crystallin incubated with Ab42 fibrils (Fig. 1 B, black squares).
The concentration of bound aB-crystallin initially increased
with total aB-crystallin concentration, and then reached a
plateau indicating saturation of the available binding sites
(Fig. 1 B, black squares). We analyzed these data using a
single binding-site model with no cooperativity. The saturation isotherm was fitted to Eq. 1 directly (Fig. 1 B, solid
black line, and Supporting Material) to determine both the
dissociation constant for the interaction of 2.1 5 0.4 mM
and the maximum molar binding ratio (MMBR) of 0.57 5
0.08 aB-crystallin monomers per Ab42 monomer. A similar
analysis was carried out for the binding of aB-crystallin to
fibrils composed of the Ab42arc peptide (Fig. 1 B, red
circles). Again aB-crystallin was observed to copellet with
the fibrils. Upon application of the single binding-site model
(Fig. 1 B, red dotted line), both the dissociation constant and
the MMBR were found to be slightly lower for these fibrils
(0.77 5 0.24 mM and 0.34 5 0.03, respectively).
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FIGURE 1 (A) Specificity of binding of aB-crystallin to Ab42 fibrils.
Solutions of 12 mM UCH-L3, GFP, and aB-crystallin in buffer A were incubated for 1 h at room temperature in the presence and absence of 12 mM
Ab42 fibrils, and then centrifuged for 30 min at 16,000  g. The supernatants were separated by SDS-PAGE, and proteins were visualized by staining with Coomassie-Blue. (B) aB-Crystallin binding to Ab42 fibrils (closed
squares) and Ab42arc fibrils (open circles). aB-Crystallin solutions of
various concentrations were incubated with 15 mM Ab fibrils at room
temperature for 1 h and then centrifuged. The concentration of aB-crystallin in the supernatant was then determined by tryptophan fluorescence as
described in Materials and Methods. The concentration of bound aB-crystallin was calculated as the difference between the estimated total concentration (from the tryptophan fluorescence of an identical solution prepared
without Ab fibrils and centrifugation) and the concentration determined
for the supernatant concentration. The lines represent the line of best fit
to the Scatchard equation for Ab42 (solid line, Vmax ¼ 8.48 5 0.49 mM
corresponding to MMBR ¼ 0.57 5 0.08, K ¼ 2.09 5 0.43 mM) and
Ab42arc (dotted line, Vmax ¼ 5.08 5 0.28 mM corresponding to
MMBR ¼ 0.34 5 0.03, K ¼ 0.77 5 0.24 mM).

Imaging of the Ab fibril complex with aB-crystallin
The high binding ratios reported above suggest that aBcrystallin binds along the entire length of the fibrils (rather
than being restricted to, e.g., the fibril ends). To investigate
this further, we visualized the fibril-chaperone complex
using immuno-EM. aB-Crystallin was incubated with fibrils
composed of Ab42 and Ab42arc peptides for 1 h at room
temperature. The fibrils were readily observed by negative
staining with uranyl acetate, and showed a morphology
Biophysical Journal 101(7) 1681–1689
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similar to that typically observed for Ab fibrils (59). By contrast, the aB-crystallin oligomer was less readily resolved
(due to its smaller relative size), and therefore samples
were immunolabeled with an antibody directed against
aB-crystallin, which was then stained with a secondary antibody conjugated to 10 nm gold nanoparticles. Immunoelectron micrographs of Ab42 and Ab42arc fibrils incubated with
aB-crystallin (Fig. 2, A and C) all show aB-crystallin to be
associated with the fibrils, with gold nanoparticles present
along the entire length of the fibrils, without any apparent
periodicity, and with occasional binding to the ends. Equivalent control samples incubated without aB-crystallin are
shown in Fig. 2, B and D. No nonspecific immunolabeling
was observed. Similar experiments with fibrils composed
of Ab40 peptide showed the same behavior (Fig. S3).

Shammas et al.

A

B

C

aB-Crystallin-mediated inhibition
of Ab fibril elongation
The binding of aB-crystallin inhibits the aggregation of
a-synuclein in solution (60,61), and it was recently shown
that binding to a-synuclein fibrils specifically and dramatically reduces the rate of fibril elongation (58). Given previous reports that aB-crystallin inhibits Ab aggregation in
solution (31), we investigated whether aB-crystallin binding
to Ab fibrils also directly inhibits fibril growth, using in situ
ThT measurements of seeded growth (Fig. 3). In the absence
of aB-crystallin, efficient seeding of fibril growth from both
Ab42 and Ab42arc fibrils was observed (Fig. 3, red circles).
Ab fibrils were incubated in the presence of aB-crystallin
(at a molar ratio of 2:1) for 1 h at room temperature to allow
saturation of aB-crystallin binding to the fibrils. We then
tested these fibrils for their seeding ability by introducing
them into a solution of low-molecular-weight (LMW) Ab

FIGURE 2 Immuno-EM of Ab42 and Ab42arc fibrils in the presence
(A and C) and absence (B and D) of aB-crystallin, respectively. All scale
bars represent 200 nm. Ab fibrils were prepared and incubated in the presence or absence of an equal molar concentration of aB-crystallin for 1 h at
room temperature. The mixtures were centrifuged at 16,000  g for 30 min,
and the pellets were resuspended and treated as described in Materials and
Methods. Similar images were observed for Ab40 fibrils (Fig. S2).
Biophysical Journal 101(7) 1681–1689

FIGURE 3 Inhibition of Ab fibril elongation by aB-crystallin binding.
Ab fibril elongation kinetics for Ab42 (A) and Ab42arc (B) fibrils (fAb) at
room temperature in buffer A in the presence and absence of aB-crystallin.
The solutions examined were LMW Ab alone (black squares), LMW Ab
with fibril seed (red circles), LMW Ab with fibril seed and a low concentration of aB-crystallin (green triangles), and LMW Ab with aB-crystallin
bound to fibril seeds (blue triangles). The fluorescence traces plotted are
the average of three replicates and are reported relative to the starting fluorescence of solutions containing Ab fibrils but no aB-crystallin. Control
solutions of LMW Ab with aB-crystallin displayed behavior similar to
that observed for LMW Ab alone. Solutions containing aB-crystallin and
ThT alone showed no change in fluorescence over these timescales. (C)
The initial elongation rates for Ab42 (black bars) and Ab42arc (white
bars) were determined from the gradient of the linear fit to the first portion
of data (1000 s for Ab42, 200 s for Ab42arc) for three repeats. Initial rates
have been normalized with respect to Ab elongation in the presence of
Ab seeds and the absence of aB-crystallin. Reported rates are the mean
and standard deviation of the three repeats. The fibril seeds were preincubated with aB-crystallin for 1 h at room temperature. Concentrations of
Ab fibrils and aB-crystallin (when present) were ~0.8 mM and 0.4 mM,
respectively. Concentrations of LMW Ab were 9.7 mM and 1.8 mM for
Ab42 and Ab42arc, respectively.

(see Supporting Material) and monitoring fibril growth via
ThT fluorescence. Fibril seeds that were preincubated with
an equivalent concentration of aB-crystallin were completely unable to seed further Ab fibril elongation. Moreover, the ThT fluorescence of the seed fibrils was
unchanged in the presence of aB-crystallin, as judged by
the fluorescence intensity at time zero (Fig. 3, A and B),
indicating that the chaperone did not disaggregate the seeds.
Upon addition of aB-crystallin (to a final concentration of
0.4 mM) to seeded Ab42, a significant decrease in the elongation rate was only observed after ~30 min (Fig. 3 A).
Together, these findings implicate a slow binding of the
chaperone to the fibril seeds as the origin of this inhibition.
It is interesting that without preincubation of Ab42 fibril

Binding of aB-Crystallin to Ab Fibrils

1685

seeds with the chaperone, inhibition of seeded growth
occurred after ~30 min after the addition of aB-crystallin
(Fig. 3 A), which may correspond to the time required for
aB-crystallin to bind to the fibrils in its active form. By
contrast, for Ab42arc, which aggregates much faster than
Ab42 (over ~10 min, compared with ~2 h), strong inhibition
was observed only when the fibril seeds were preincubated
with the chaperone (Fig. 3 B).
We also examined the inhibition of Ab fibril growth using
a QCM. In previous applications of this technique, we
showed that when preformed seed fibrils are attached to
the surface of the quartz crystal, this kinetic assay is highly
specific for the elongation step of the overall fibrillization
pathway (45,58,62,63). Ab42 fibrils were covalently
attached to the surface of the sensor crystal as previously
described (63). Their rate of elongation was then observed
as a change in the resonant frequency of the quartz sensor,
which reflects an increase in the surface-bound mass (see
Materials and Methods for details). A QCM sensor crystal
covered with Ab42 fibril seeds was exposed to solutions of
LMW Ab42 and aB-crystallin. Exposure of QCM sensors
with no attached seeds to LMW Ab does not result in a
significant change in the resonant frequency of the system
(63). In contrast, exposure of QCM sensors covered with
Ab42 fibril seeds to LMW Ab42 yielded a linear decrease
in resonant frequency over the course of several minutes,
corresponding to a steady rate of fibril elongation (see

A

C

Fig. 3 A). The introduction of 2.5 mM aB-crystallin caused
a decrease in frequency that showed a different kinetic
profile, namely, a saturable attachment of the chaperone to
the surface (Fig. 4 A). Nonspecific adsorption of aB-crystallin was also observed for QCM sensors without attached
fibril seeds; however, the observed increase in mass was
less extensive than that found in the presence of bound seeds
(Fig. S4 B). Once the fibrils had been exposed to aB-crystallin, they lost the ability to support further Ab monomer
deposition, when probed by renewed incubation of the
sensor surface with Ab42 solution (Fig. 4, A and B). Control
experiments demonstrated that renewed incubation of the
surface-bound seeds with LMW Ab resulted in additional
fibril elongation if there was no intermittent contact with
aB-crystallin (Fig. S4 A). Because the chaperone and Ab
solutions were added sequentially with an intervening buffer
wash of the liquid cell, the deactivation of fibril growth sites
by chaperone binding, rather than the sequestration of amyloidogenic species in solution, must be responsible for the
observed inhibition of increasing mass. After the QCM
experiments, we acquired atomic force microscopy images
of the functionalized sensors using tapping mode in air,
and observed that the fibrils had lengthened (Fig. 4, C and
D). Finally, we investigated the reversibility of the inhibition
by allowing the aB-crystallin to dissociate from the fibril
seeds by washing with a 3 M solution of the denaturant
guanidinium chloride (this concentration was shown not to

B

D

FIGURE 4 (A) Inhibition of Ab42 fibril elongation by aB-crystallin probed by QCM. A decrease
in resonant frequency (overtone with N ¼ 3 shown)
indicates attachment of protein. At 38 C, Ab fibrils
were incubated in buffer C (100 mM phosphate,
pH 7.4) before injection of 1.7 mM LMW Ab42.
Buffer C then replaced the Ab42 solution, quenching amyloid fibril elongation. After incubations
with 2.5 mM aB-crystallin, the Ab42 fibril chip
was again exposed to a solution of 1.7 mM LMW
Ab42, which did not lead to a frequency shift comparable to that observed during the first incubation
with LMW Ab42, demonstrating the inhibitory
effect of aB-crystallin. (B) The rate of frequency
drop for the two periods of Ab42 exposure determined from straight line fitting. The error bars
represent the largest variation between the overall
rate and local rates during the second exposure.
AFM images of typical QCM sensor surfaces
before (C) and after (D) exposure to Ab solutions
demonstrate fibril elongation.
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dissolve Ab fibrils; data not shown). Subsequently, these
seeds were able to elongate again when exposed to LMW
Ab42 (Fig S4 C).
DISCUSSION
Amyloid fibrils are not simply inert products of protein
aggregation; rather, they are dynamic species that have the
ability not only to grow but also to fragment and dissociate
(43,64). Given the association of aB-crystallin (7,24) and
other sHsps with Ab plaques in AD, we investigated
whether this archetypical sHsp chaperone has the ability
to influence one of the crucial stages of fibril formation,
the elongation phase of amyloid growth. We demonstrated
in this study that aB-crystallin selectively binds to Ab42
and Ab42arc fibrils with micromolar affinity, with high
MMBRs for aB-crystallin (Ab ¼ 0.57 5 0.08 and 0.34 5
0.03, respectively). These values are highly consistent with
immuno-EM data showing that the chaperone molecules
bind along the length and at the ends of the fibrils. A previously described simple geometric model (58) indicated
values of 0.2–0.7 for maximum coverage of the fibril. To
elucidate the consequences of this interaction, we performed
investigations into the effects of aB-crystallin on seeded Ab
fibril growth, both in solution and on the surface of a QCM
biosensor. We observed that while bound, aB-crystallin
strongly retards the rate of fibril elongation (Figs. 3 and 4),
and that once it is removed, fibril elongation can be resumed
(Fig. S4 C). The significant difference in seeding efficiency
between fibrils with bound aB-crystallin and fibrils with
unbound aB-crystallin (Fig. 3) demonstrates that aB-crystallin binding to fibrils can directly inhibit fibril growth.
This result is inconsistent with inhibition due to chaperone
binding to Ab monomer or early oligomers, because a larger
concentration of aB-crystallin is available for binding these
species in the latter case, where no inhibition is observed.
The process of protein aggregation and amyloid formation is characterized by sigmoidal assembly kinetics, with
a lag phase before rapid growth. The duration of the lag
phase is usually shown to be heavily dominated by the rates
of elongation and fragmentation while varying only logarithmically with the nucleation rate (43). With such a
scenario, the most effective way to extend the lag phase
would be to reduce the elongation or fragmentation rate,
not the nucleation rate. Hence, the binding of a chaperone
to fibrils to inhibit their further elongation, as observed
here, is very likely to be critical and highly influential mechanistically, in terms of an effective inhibitory activity of the
chaperone. Binding along the fibril length (l) may appear to
be a fairly inefficient mechanism for inhibiting fibril elongation, because for a cylinder of radius r, only a proportion
r/(rþl) of the area is at the ends. In the initial stages of
aggregation, the fibrils/fibril precursors are much shorter,
making it more efficient than in the case of mature fibrils.
For example, for fibrils of radius 2–5 nm (as suggested by
Biophysical Journal 101(7) 1681–1689
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AFM images) and short fibrils of ~20 nm, these calculations
suggest ratios of 11:1 to 5:1. In addition, binding of the sHsp
to the fibril could also serve additional roles, such as
coverage of potentially toxic fibril surfaces (65), affecting
fibril fragmentation rates, or targeting the fibrils for degradation (30).
We recently showed, using immunogold labeling TEM,
that aB-crystallin can also bind to amyloid fibrils formed
from an alternative target protein, a-synuclein (58). The
binding interaction suppressed a-synuclein fibril elongation
in a manner analogous to that found here for aB-crystallin
with Ab amyloid fibrils. This anti-aggregation activity of
aB-crystallin toward the elongation phase of amyloid
assembly could be a general mechanistic phenomenon involving sHsps and many or all amyloid fibrils. This conclusion is further supported by the observation from QCM
studies that aB-crystallin inhibits the elongation of insulin
amyloid fibrils (45).
It is interesting that fibrils formed from two different Ab
peptides showed similar MMBR values for aB-crystallin
binding, despite significant differences in their capacity to
bind ThT (data not shown). They are also comparable to
the approximate MBR determined from a-synuclein fibrils
(58), which may represent further evidence for a common
mechanism of binding of aB-crystallin to amyloid fibrils.
The fact that the measured ThT fluorescence of the fibril
seeds is not diminished by the addition of aB-crystallin
(Fig. 3) suggests that the mechanism and/or region of chaperone binding is distinct from that of the ThT dye. aB-Crystallin binds target proteins in part via exposed regions of
hydrophobicity (21,31,66); hence, it is possible that aBcrystallin binds to amyloid fibrils through association with
hydrophobic regions of the Ab peptides or a-synuclein
that protrude from the main cross-b amyloid fibril core.
Assuming that the chaperone activity of aB-crystallin is
in part mediated by its ability to bind to patches of exposed
hydrophobicity on aggregation-prone target proteins
(21,31,66), it is likely that this sHsp associates with additional species on the amyloid formation pathway that also
have exposed hydrophobic regions. Indeed, a weak and transient interaction was previously proposed for aB-crystallin
with Ab monomers (57). Consistent with this, the interaction
of aB-crystallin with species early along the a-synuclein
fibril-forming pathway has been well characterized (60,61).
Typically, sHsps (including aB-crystallin (31)) are localized inside cells as cytoplasmic proteins, although there
have been reports of extracellular sHsps (67). The association of aB-crystallin with Ab peptides in AD plaques, which
are extracellular, may therefore be a result of their release
from cells after damage associated with Ab oligomers,
which are proposed to be the primary neurotoxic species.
Of interest, Friedrich et al. (68) recently showed that in
cell culture, Ab plaque formation occurs intracellularly
and leads to cell death before the plaques are released into
the extracellular space. Thus, because of the significant
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intracellular phase of Ab aggregation, there may be ample
opportunity for Ab to interact with aB-crystallin and other
sHsps. A number of studies have suggested that aB-crystallin can influence amyloid fibril assembly via interactions
with early-stage fibrillar oligomers. For example, it has
been shown that aB-crystallin can redirect the amyloidogenic a-synuclein protein toward an amorphous aggregation
pathway with more easily degradable end products (60).
One study indicated that aB-crystallin not only inhibits
amyloid fibril formation by the Ab peptides but also promotes the formation of alternative stable structures that
are more toxic to cells (52). However, a more recent study
showed that aB-crystallin inhibits amyloid fibril formation
and its associated cell toxicity for both k-casein and Ab40
peptides (56). aB-Crystallin is much more efficient at
inhibiting slowly aggregating target proteins along the
amorphous (69) and fibril-forming (61,70–72) pathways.
Consistent with this finding, we observed that because of
its slower aggregation rate, Ab42 enabled aB-crystallin to
interact with its fibrils to partially inhibit fibril growth
(Fig. 3 A), whereas LMW Ab42arc and fAb42arc did not
(Fig. 3 B). Further investigations into the specific mechanistic processes involved in the interaction between aBcrystallin and isolated oligomeric Ab amyloid intermediates
will therefore be of interest.
It is interesting to speculate about the physiological implications of the interactions between aB-crystallin and elongating
fibrils described here, and the influence these processes may
have on their links with disease. As described earlier, the elongation phase is critical for determining the overall kinetics of
the process of amyloid assembly (43), and hence a chaperone
that is capable of inhibiting this stage of amyloid growth is
likely to be a powerful suppressor of fibril proliferation.
Further, the ability of aB-crystallin to bind fibrils with micromolar affinity is interesting in view of recent reports that sHsps
are able not only to inhibit aggregation but also to target
substrates for degradation (30). It is therefore possible that
this binding interaction could be valuable for promoting the
disposal of amyloidogenic species in vivo.
CONCLUSIONS
In summary, the data presented here reveal that aB-crystallin binds to Ab amyloid fibrils, and through this interaction
suppresses the elongation phase of Ab42 fibril growth in
a highly effective manner. Given the increasing number of
amyloid fibril systems in which this behavior has now
been observed (e.g., Ab40, Ab42, Ab42arc, a-synuclein, and
insulin), this activity appears to be a generic function of
this archetypical sHsp, whereby it displays chaperone
behavior toward all amyloid fibrils regardless of their
constituent target proteins. Overall, therefore, it is likely
that all species along the amyloid fibril-forming pathway,
including oligomers and fibrils, will interact with molecular
chaperones, such as sHsps, because all are misfolded and
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potentially expose hydrophobic regions. This process may
offer a more comprehensive protection against the toxicity
associated with amyloid fibrils than that obtained from interaction with the monomeric or oligomeric species only.
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Specific association of small heat shock proteins with the pathological
hallmarks of Alzheimer’s disease brains. Neuropathol. Appl.
Neurobiol. 32:119–130.
9. Renkawek, K., C. E. Voorter, ., W. W. de Jong. 1994. Expression of
aB-crystallin in Alzheimer’s disease. Acta Neuropathol. 87:155–160.
10. Bhat, S. P., and C. N. Nagineni. 1989. aB subunit of lens-specific
protein a-crystallin is present in other ocular and non-ocular tissues.
Biochem. Biophys. Res. Commun. 158:319–325.
11. Bhat, S. P., J. Horwitz, ., L. Ding. 1991. aB-crystallin exists as an
independent protein in the heart and in the lens. Eur. J. Biochem.
202:775–781.
12. Nagineni, C. N., and S. P. Bhat. 1989. aB-crystallin is expressed
in kidney epithelial cell lines and not in fibroblasts. FEBS Lett.
249:89–94.
13. May, C. A., B. Arnold, ., E. Lütjen-Drecoll. 1998. aB-crystallin in
the mammalian inner ear. ORL J. Otorhinolaryngol. Relat. Spec. 60:
121–125.
Biophysical Journal 101(7) 1681–1689

1688
14. May, C. A., U. Welge-Lüssen, ., E. Lütjen-Drecoll. 2000. aB-crystallin in lacrimal gland duct and tears. Curr. Eye Res. 21:588–594.
15. Augusteyn, R. C. 2010. On the growth and internal structure of the
human lens. Exp. Eye Res. 90:643–654.
16. de Jong, W. W., J. A. Leunissen, and C. E. Voorter. 1993. Evolution of
the a-crystallin/small heat-shock protein family. Mol. Biol. Evol.
10:103–126.
17. Goldstein, L. E., J. A. Muffat, ., A. I. Bush. 2003. Cytosolic
b-amyloid deposition and supranuclear cataracts in lenses from people
with Alzheimer’s disease. Lancet. 361:1258–1265.
18. Aquilina, J. A., J. L. P. Benesch, ., C. V. Robinson. 2003. Polydispersity of a mammalian chaperone: mass spectrometry reveals the population of oligomers in aB-crystallin. Proc. Natl. Acad. Sci. USA.
100:10611–10616.
19. Jehle, S., B. van Rossum, ., P. Rajagopal. 2009. aB-crystallin:
a hybrid solid-state/solution-state NMR investigation reveals structural
aspects of the heterogeneous oligomer. J. Mol. Biol. 385:1481–1497.
20. MacRae, T. H. 2000. Structure and function of small heat shock/a-crystallin proteins: established concepts and emerging ideas. Cell. Mol. Life
Sci. 57:899–913.
21. Treweek, T. M., A. M. Morris, and J. A. Carver. 2003. Intracellular
protein unfolding and aggregation: the role of small heat-shock chaperone proteins. Aust. J. Chem. 56:357–367.
22. Carver, J. A., J. A. Aquilina, ., G. B. Ralston. 1992. Identification by
1H NMR spectroscopy of flexible C-terminal extensions in bovine lens
a-crystallin. FEBS Lett. 311:143–149.
23. Laganowsky, A., J. L. P. Benesch, ., D. Eisenberg. 2010. Crystal
structures of truncated aA and aB crystallins reveal structural mechanisms of polydispersity important for eye lens function. Protein Sci.
19:1031–1043.
24. Sun, Y., and T. H. MacRae. 2005. Small heat shock proteins: molecular
structure and chaperone function. Cell. Mol. Life Sci. 62:2460–2476.
25. Bova, M. P., H. S. McHaourab, ., B. K. Fung. 2000. Subunit exchange
of small heat shock proteins. Analysis of oligomer formation of aAcrystallin and Hsp27 by fluorescence resonance energy transfer and
site-directed truncations. J. Biol. Chem. 275:1035–1042.
26. Burgio, M. R., P. M. Bennett, and J. F. Koretz. 2001. Heat-induced
quaternary transitions in hetero- and homo-polymers of a-crystallin.
Mol. Vis. 7:228–233.
27. Haley, D. A., J. Horwitz, and P. L. Stewart. 1998. The small heat-shock
protein, aB-crystallin, has a variable quaternary structure. J. Mol. Biol.
277:27–35.
28. Peschek, J., N. Braun, ., J. Buchner. 2009. The eye lens chaperone
a-crystallin forms defined globular assemblies. Proc. Natl. Acad. Sci.
USA. 106:13272–13277.
29. Horwitz, J. 1992. a-crystallin can function as a molecular chaperone.
Proc. Natl. Acad. Sci. USA. 89:10449–10453.
30. Carra, S., J. F. Brunsting, ., H. H. Kampinga. 2009. HspB8 participates in protein quality control by a non-chaperone-like mechanism
that requires eIF2a phosphorylation. J. Biol. Chem. 284:5523–5532.

Shammas et al.
36. Kawarabayashi, T., M. Shoji, ., S. G. Younkin. 2004. Dimeric
amyloid b protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse
model of Alzheimer’s disease. J. Neurosci. 24:3801–3809.
37. Sondag, C. M., G. Dhawan, and C. K. Combs. 2009. b amyloid oligomers and fibrils stimulate differential activation of primary microglia.
J. Neuroinflammation. 6:1.
38. Catalano, S. M., E. C. Dodson, ., G. G. Kinney. 2006. The role of
amyloid-b derived diffusible ligands (ADDLs) in Alzheimer’s disease.
Curr. Top. Med. Chem. 6:597–608.
39. Hepler, R. W., K. M. Grimm, ., J. G. Joyce. 2006. Solution state characterization of amyloid b-derived diffusible ligands. Biochemistry.
45:15157–15167.
40. Wang, H.-W., J. F. Pasternak, ., B. L. Trommer. 2002. Soluble oligomers of b amyloid (1-42) inhibit long-term potentiation but not longterm depression in rat dentate gyrus. Brain Res. 924:133–140.
41. Lord, A., H. Englund, ., L. N. Nilsson. 2009. Amyloid-b protofibril
levels correlate with spatial learning in Arctic Alzheimer’s disease
transgenic mice. FEBS J. 276:995–1006.
42. Nilsberth, C., A. Westlind-Danielsson, ., L. Lannfelt. 2001. The
‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by
enhanced Ab protofibril formation. Nat. Neurosci. 4:887–893.
43. Knowles, T. P. J., C. A. Waudby, ., C. M. Dobson. 2009. An analytical
solution to the kinetics of breakable filament assembly. Science.
326:1533–1537.
44. Tanaka, M., S. R. Collins, ., J. S. Weissman. 2006. The physical basis
of how prion conformations determine strain phenotypes. Nature.
442:585–589.
45. Knowles, T. P. J., W. Shu, ., M. E. Welland. 2007. Kinetics and thermodynamics of amyloid formation from direct measurements of fluctuations in fibril mass. Proc. Natl. Acad. Sci. USA. 104:10016–10021.
46. Orte, A., N. R. Birkett, ., D. Klenerman. 2008. Direct characterization
of amyloidogenic oligomers by single-molecule fluorescence. Proc.
Natl. Acad. Sci. USA. 105:14424–14429.
47. Dobson, C. M. 2003. Protein folding and misfolding. Nature. 426:
884–890.
48. Pawar, A. P., K. F. Dubay, ., C. M. Dobson. 2005. Prediction of
‘‘aggregation-prone’’ and ‘‘aggregation-susceptible’’ regions in proteins associated with neurodegenerative diseases. J. Mol. Biol. 350:
379–392.
49. Borchelt, D. R., G. Thinakaran, ., S. S. Sisodia. 1996. Familial Alzheimer’s disease-linked presenilin 1 variants elevate Ab1-42/1-40 ratio
in vitro and in vivo. Neuron. 17:1005–1013.
50. Scheuner, D., C. Eckman, ., S. Younkin. 1996. Secreted amyloid
b-protein similar to that in the senile plaques of Alzheimer’s disease
is increased in vivo by the presenilin 1 and 2 and APP mutations linked
to familial Alzheimer’s disease. Nat. Med. 2:864–870.
51. Sgarbossa, A., D. Buselli, and F. Lenci. 2008. In vitro perturbation of
aggregation processes in b-amyloid peptides: a spectroscopic study.
FEBS Lett. 582:3288–3292.

31. Ecroyd, H., and J. A. Carver. 2009. Crystallin proteins and amyloid
fibrils. Cell. Mol. Life Sci. 66:62–81.

52. Stege, G. J., K. Renkawek, ., W. W. de Jong. 1999. The molecular
chaperone aB-crystallin enhances amyloid b neurotoxicity. Biochem.
Biophys. Res. Commun. 262:152–156.

32. Knowles, T. P., A. W. Fitzpatrick, ., M. E. Welland. 2007. Role of
intermolecular forces in defining material properties of protein nanofibrils. Science. 318:1900–1903.

53. Raman, B., T. Ban, ., ChM. Rao. 2005. aB-crystallin, a small heatshock protein, prevents the amyloid fibril growth of an amyloid
b-peptide and b2-microglobulin. Biochem. J. 392:573–581.

33. Chiti, F., and C. M. Dobson. 2006. Protein misfolding, functional
amyloid, and human disease. Annu. Rev. Biochem. 75:333–366.

54. Wilhelmus, M. M. M., W. C. Boelens, ., M. M. Verbeek. 2006. Small
heat shock proteins inhibit amyloid-b protein aggregation and cerebrovascular amyloid-b protein toxicity. Brain Res. 1089:67–78.

34. Hung, L. W., G. D. Ciccotosto, ., K. J. Barnham. 2008. Amyloidb peptide (Ab) neurotoxicity is modulated by the rate of peptide aggregation: Ab dimers and trimers correlate with neurotoxicity. J. Neurosci.
28:11950–11958.

55. Kudva, Y. C., H. J. Hiddinga, ., N. L. Eberhardt. 1997. Small heat
shock proteins inhibit in vitro A b(1-42) amyloidogenesis. FEBS
Lett. 416:117–121.

35. Cleary, J. P., D. M. Walsh, ., K. H. Ashe. 2005. Natural oligomers
of the amyloid-b protein specifically disrupt cognitive function. Nat.
Neurosci. 8:79–84.

56. Dehle, F. C., H. Ecroyd, ., J. A. Carver. 2010. aB-Crystallin inhibits
the cell toxicity associated with amyloid fibril formation by k-casein
and the amyloid-b peptide. Cell Stress Chaperones. 15:1013–1026.

Biophysical Journal 101(7) 1681–1689

Binding of aB-Crystallin to Ab Fibrils
57. Narayanan, S., B. Kamps, ., B. Reif. 2006. aB-crystallin competes
with Alzheimer’s disease b-amyloid peptide for peptide-peptide interactions and induces oxidation of Ab-Met35. FEBS Lett. 580:5941–
5946.
58. Waudby, C. A., T. P. J. Knowles, ., S. Meehan. 2010. The interaction
of aB-crystallin with mature a-synuclein amyloid fibrils inhibits their
elongation. Biophys. J. 98:843–851.
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